See more : Dream Homes & Development Corporation (DREM) Income Statement Analysis – Financial Results
Complete financial analysis of Metacrine, Inc. (MTCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Metacrine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bonus BioGroup Ltd. (BONS.TA) Income Statement Analysis – Financial Results
- The Coretec Group Inc. (CRTG) Income Statement Analysis – Financial Results
- Mallee Resources Limited (MYL.AX) Income Statement Analysis – Financial Results
- Rouchon Industries, Inc. (RCHN) Income Statement Analysis – Financial Results
- Aikchol Hospital Public Company Limited (AHC.BK) Income Statement Analysis – Financial Results
Metacrine, Inc. (MTCR)
About Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.45M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 1.45M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 45.47M | 26.79M | 25.97M | 22.94M |
| General & Administrative | 15.61M | 9.90M | 4.03M | 5.24M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 9.90M | 4.03M | 5.24M |
| Other Expenses | 0.00 | -614.00K | 0.00 | 0.00 |
| Operating Expenses | 61.08M | 36.69M | 30.00M | 28.18M |
| Cost & Expenses | 61.08M | 36.69M | 30.00M | 28.18M |
| Interest Income | 102.00K | 494.00K | 1.42M | 934.00K |
| Interest Expense | 1.20M | 1.01M | 347.00K | 0.00 |
| Depreciation & Amortization | 972.00K | 931.00K | 2.25M | 829.00K |
| EBITDA | -61.08M | -36.69M | -27.76M | -24.99M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,723.59% |
| Operating Income | -61.08M | -36.69M | -30.00M | -26.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,843.38% |
| Total Other Income/Expenses | -1.13M | -614.00K | 1.07M | 908.00K |
| Income Before Tax | -62.21M | -37.30M | -28.93M | -25.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,780.76% |
| Income Tax Expense | -972.00K | -931.00K | 347.00K | 908.00K |
| Net Income | -61.24M | -36.37M | -29.28M | -25.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,780.76% |
| EPS | -1.45 | -3.87 | -1.52 | -1.35 |
| EPS Diluted | -1.45 | -3.87 | -1.52 | -1.35 |
| Weighted Avg Shares Out | 42.11M | 9.40M | 19.22M | 19.06M |
| Weighted Avg Shares Out (Dil) | 42.11M | 9.40M | 19.22M | 19.06M |
Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch
Penny stocks to buy under $1: A Beginner's Guide The post Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Metacrine: Potential Play On A Higher Bid
Metacrine is getting acquired by Equillium in an all-stock transaction at an exchange ratio of 0.282x. Due to a decline in EQ share price since the announcement, the offer currently values MTCR at a 45% discount to net cash.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, ECOM, MTCR, MNRL
NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CarLotz, Inc....
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Equillium, Inc....
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR
NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ChannelAdvisor Corporation...
Metacrine To Slash Its Workforce By 50%
Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in 2020 at $13/share.
Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
Investors need to pay close attention to Metacrine (MTCR) stock based on the movements in the options market lately.
3 Penny Stocks To Watch After Jerome Powell's Fed Announcement
3 penny stocks to watch after Fed Chair Powells press conference. The post 3 Penny Stocks To Watch After Jerome Powell's Fed Announcement appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET642, an...
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday,...
Source: https://incomestatements.info
Category: Stock Reports